SCHEMBL3000736

SCHEMBL3000736

CCS(=O)(=O)N1CCN(c2cccc(OC)c2C2C(C(=O)OCc3ccccc3)=C(C)Nc3nnnn32)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.53
LMNA P02545 5/20 0.53
POLB P06746 2/20 0.53
PKM P14618 1/20 0.53
HSD17B10 Q99714 3/20 0.48
TSHR P16473 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265866 0.87 PKM (0.46) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3002849 0.83 ALDH1A1 (0.64) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL2992376 0.83 ALDH1A1 (0.63) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3004329 0.82 ALDH1A1 (0.57) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3004269 0.79 ALDH1A1 (0.64) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3010286 0.78 ALDH1A1 (0.61) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3004455 0.78 ALDH1A1 (0.61) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3006499 0.77 ALDH1A1 (0.62) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL4257317 0.77 PKM (0.59) ALDH1A1LMNAPOLBPKMHSD17B10
SCHEMBL3005539 0.76 PKM (0.65) ALDH1A1LMNAPOLBPKMHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885LMNA 738/4885POLB 3337/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885LMNA 738/4885POLB 3337/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885LMNA 738/4885POLB 3337/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885LMNA 738/4885POLB 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.